Latest Galderma Laboratories Stories
SCHAUMBURG, Ill. and SOPHIA ANTIPOLIS, FRANCE, April 25, 2013 /PRNewswire/ -- The American Academy of Dermatology (Academy), in partnership with Galderma Research & Development, SNC is pleased to announce the creation of the American Academy of Dermatology Translational Biotechnology Fellowship. The new fellowship will offer a dermatologist the opportunity to work in drug development and translational medical research at Galderma's R&D facility located in Sophia Antipolis,...
BASKING RIDGE, N.J., March 21, 2013 /PRNewswire/ -- Galderma, a leading global pharmaceutical company focused on dermatology, wanted a cost-efficient means of increasing the capacity of its IT global network infrastructure to support its increasingly data-intensive workload. The company chose a fully managed communications network from Verizon Enterprise Solutions, underpinned by Verizon's comprehensive security solutions and professional service expertise. The result is a secure,...
FORT WORTH, Texas, Aug. 6, 2012 /PRNewswire/ -- Galderma Laboratories, L.P., part of a global pharmaceutical company exclusively focused on dermatology, has pledged $450,000 to help support the dermatology residency program at Baylor University Medical Center at Dallas. The pledge brings Galderma's support of the program to $900,000 since its inception. The dermatology residency program at Baylor Dallas was initiated by Galderma's initial gift in 2009 that provided the program's first...
MISSISSAUGA, ON, July 19, 2012 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain today announced that Galderma S.A. (Galderma), a global company dedicated to dermatology has received its first three Pliaglis marketing licenses from E.U. countries These licenses entitle Nuvo to receive a total of US$6.0 million of milestone payments from its worldwide Pliaglis marketing...
MISSISSAUGA, ON, May 8, 2012 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, announced that Galderma Laboratories, L.P., the U.S. affiliate of Galderma S.A. (Galderma) has responded to the U.S. Food and Drug Administration (FDA) Complete Response Letter for Pliaglis (lidocaine and tetracaine Cream...
-- Enters national licensing phase in 17 E.U. countries MISSISSAUGA, ON, May 7, 2012 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced that it has received notice of a positive opinion from the European Decentralized Procedure for the approval of Pliaglis from the German...
MISSISSAUGA, ON, May 2, 2012 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced its financial and operational results for the first quarter ended March 31, 2012. First Quarter and Recent Corporate Developments: -- Pennsaid® U.S. prescriptions continued to grow...
OCEANSIDE, N.Y., April 10, 2012 /PRNewswire/ -- Ellman International, Inc. announced the appointment of Dave Pfeiffer to the position of Executive Vice President and Chief Commercial Officer. Mr. Pfeiffer will be responsible for all domestic & international commercial activities. Mr. Pfeiffer, previously a member of the Board of Directors of Ellman International, will report to Frank D'Amelio, CEO of Ellman. Also continuing as part of the Senior Management team is Mike Kucza,...
FORT WORTH, Texas, March 13, 2012 /PRNewswire/ -- Cetaphil®, the #1 dermatologist-recommended brand of cleansers and moisturizers, today announced the launch of Cetaphil® DermaControl(TM) products, formulated for acne-prone skin. Cetaphil® DermaControl(TM) is the first skin care line of its kind designed to complement an acne regimen for sensitive, acne-prone skin. Delivered through advanced technology, the Cetaphil®DermaControl(TM) skincare system is one of the first to...
MISSISSAUGA, ON, Feb. 29, 2012 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced its financial and operational results for the fourth quarter and year ended December 31, 2011. Fourth Quarter and Recent Corporate Developments: -- Pennsaid® U.S. prescriptions continue to grow...
